HVTN 140/HPTN 101

A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV uninfected adult participants.


The HVTN 140/HPTN 101 study wants to understand how the body’s immune system responds to a new lab-made antibody against HIV (Human Immunodeficiency Virus). The antibodies will be delivered directly into the body through Subcutaneous and Intravenous infusion (under the skin on your abdomen, arm, hand, or thigh).  We are hoping that if this new HIV Prevention method is approved, we will have more options for HIV Prevention and treatment.


  • Prof Sinead Delany-Moretlwe, IOR
  • Dr Carrie-Anne Mathew, Sub Investigator
  • Dr Juliet Vimbai Rundogo, Sub Investigator

Latest Update:

April 2024

For more about HVTN 140/HPTN 101 please email

Study Brief

HVTN 140/HPTN 101

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.